Rapid development of an inactivated vaccine for SARS-CoV-2
By
Qiang Gao,
Linlin Bao,
Haiyan Mao,
Lin Wang,
Kangwei Xu,
Minnan Yang,
Yajing Li,
Ling Zhu,
Nan Wang,
Zhe Lv,
Hong Gao,
Xiaoqin Ge,
Biao Kan,
Yaling Hu,
Jiangning Liu,
Fang Cai,
Deyu Jiang,
Yanhui Yin,
Chengfeng Qin,
Jing Li,
Xuejie Gong,
Xiuyu Lou,
Wen Shi,
Dongdong Wu,
Hengming Zhang,
Lang Zhu,
Wei Deng,
Yurong Li,
Jinxing Lu,
Changgui Li,
Xiangxi Wang,
Weidong Yin,
Yanjun Zhang,
Chuan Qin
Posted 19 Apr 2020
bioRxiv DOI: 10.1101/2020.04.17.046375
(published DOI: 10.1126/science.abc1932)
The COVID-19 caused by SARS-CoV-2 has brought about an unprecedented crisis, taking a heavy toll on human health, lives as well as the global economy. There are no SARS-CoV-2-specific treatments or vaccines available due to the novelty of this virus. Hence, rapid development of effective vaccines against SARS-CoV-2 is urgently needed. Here we developed a pilot-scale production of a purified inactivated SARS-CoV-2 virus vaccine candidate (PiCoVacc), which induced SARS-CoV-2-specific neutralizing antibodies in mice, rats and non-human primates. These antibodies potently neutralized 10 representative SARS-CoV-2 strains, indicative of a possible broader neutralizing ability against SARS-CoV-2 strains circulating worldwide. Immunization with two different doses (3 μg or 6 μg per dose) provided partial or complete protection in macaques against SARS-CoV-2 challenge, respectively, without any antibody-dependent enhancement of infection. Systematic evaluation of PiCoVacc via monitoring clinical signs, hematological and biochemical index, and histophathological analysis in macaques suggests that it is safe. These data support the rapid clinical development of SARS-CoV-2 vaccines for humans. ### Competing Interest Statement The authors have declared no competing interest.
Download data
- Downloaded 86,405 times
- Download rankings, all-time:
- Site-wide: 53
- In microbiology: 6
- Year to date:
- Site-wide: 351
- Since beginning of last month:
- Site-wide: 334
Altmetric data
Downloads over time
Distribution of downloads per paper, site-wide
PanLingua
News
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!